Monoclonal antibodies for the treatment of osteoporosis

Bibliography

• Cooper C, Campion G, Melton LJ III. Hip fractures in the elderly: a world-wide projection. Osteoporos Int 1992;2(6):285-9
   PubMed Web of Science ®Google Scholar
• Klibanski A, Adams-Campbell L, Bassford T, Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285(6):785-95
   PubMed Web of Science ®Google Scholar
• Melton LJ III, Chrischilles EA, Cooper C, Perspective. How many women have osteoporosis? J Bone Miner Res 1992;7(9):1005-10
   PubMed Web of Science ®Google Scholar
• Center JR, Nguyen TV, Schneider D, Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353(9156):878-82
   PubMed Web of Science ®Google Scholar
• Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med 1997;103(2A):12S-9S
   PubMedGoogle Scholar
• World Health Organisation. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO; Geneva, Switzerland: 1994
   Google Scholar
• Baim S, Binkley N, Bilezikian JP, Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom 2008;11(1):75-91
   PubMed Web of Science ®Google Scholar
• World Health Organization: FRAX WHO Fracture Risk Assessment Tool. Available from: http://www.shef.ac.uk/FRAX/ [Accessed October 2012]
   Google Scholar
• Kanis JA. On behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health-care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases; University of Sheffield, UK: Printed by the University of Sheffield 2007
   Google Scholar
• Wainwright SA, Marshall LM, Ensrud KE, Hip fracture in women without osteoporosis. J Clin Endocrinol Metab 2005;90(5):2787-93
   PubMed Web of Science ®Google Scholar
• National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation; Washington, DC: 2008
   Google Scholar
• Kanis JA, Burlet N, Cooper C, European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008;19(4):399-428
   PubMed Web of Science ®Google Scholar
• Fujiwara S, Nakamura T, Orimo H, Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos Int 2008;19(4):429-35
   PubMed Web of Science ®Google Scholar
• Siminoski K, Leslie WD, Frame H, Recommendations for bone mineral density reporting in Canada: a shift to absolute fracture risk assessment. J Clin Densitom 2007;10(2):120-3
   PubMed Web of Science ®Google Scholar
• Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291(14):1701-12
   PubMed Web of Science ®Google Scholar
• Liberman UA, Weiss SR, Broll J, Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB, Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Thompson DE, Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures - Results from the fracture intervention trial. JAMA 1998;280(24):2077-82
   PubMed Web of Science ®Google Scholar
• McClung MR, Geusens P, Miller PD, Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-40
   PubMed Web of Science ®Google Scholar
• Reginster J-Y, Minne HW, Sorensen OH, Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282(14):1344-52
   PubMed Web of Science ®Google Scholar
• Chesnut CH III, Skag A, Christiansen C, Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19(8):1241-9
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356(18):1809-22
   PubMed Web of Science ®Google Scholar
• Lyles KW, Colon-Emeric CS, Magaziner JS, Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357(18):1799-809
   PubMed Web of Science ®Google Scholar
• Chesnut CH III, Silverman S, Andriano K, A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109(4):267-76
   PubMed Web of Science ®Google Scholar
• Reginster JY, Seeman E, De Vernejoul MC, Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90(5):2816-22
   PubMed Web of Science ®Google Scholar
• Meunier PJ, Roux C, Seeman E, The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350(5):459-68
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH, Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene - Results from a 3-year randomized clinical trial. JAMA 1999;282(7):637-45
   PubMed Web of Science ®Google Scholar
• Silverman SL, Christiansen C, Genant HK, Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008;23(12):1923-34
   PubMed Web of Science ®Google Scholar
• Cummings SR, Eastell R, Ensrud K, The effects of lasofoxifene on fractures and breast cancer: 3-year results from the PEARL trial. J Bone Miner Res 2008;23(Suppl 1):S81
   Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41
   PubMed Web of Science ®Google Scholar
• Greenspan SL, Bone HG, Ettinger MP, Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007;146(5):326-39
   PubMed Web of Science ®Google Scholar
• Cummings SR, San Martin J, McClung MR, Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361(8):756-65
   PubMed Web of Science ®Google Scholar
• Curtis JR, Carbone L, Cheng H, Longitudinal trends in use of bone mass measurement among older Americans, 1999-2005. J Bone Miner Res 2008;23(7):1061-7
   PubMed Web of Science ®Google Scholar
• Foley KA, Foster SA, Meadows ES, Assessment of the clinical management of fragility fractures and implications for the new HEDIS osteoporosis measure. Med Care 2007;45(9):902-6
   PubMed Web of Science ®Google Scholar
• McCombs JS, Thiebaud P, Laughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48(3):271-87
   PubMed Web of Science ®Google Scholar
• Caro JJ, Ishak KJ, Huybrechts KF, The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15(12):1003-8
   PubMed Web of Science ®Google Scholar
• Guntur AR, Rosen CJ. Bone as an endocrine organ. Endocr Pract 2012;1-15; Epub ahead of print
   Google Scholar
• Karsenty G, Oury F. Biology without walls: the novel endocrinology of bone. Annu Rev Physiol 2012;74:87-105
   PubMed Web of Science ®Google Scholar
• Lewiecki EM. Combination therapy: the Holy Grail for the treatment of postmenopausal osteoporosis? Curr Med Res Opin 2011;27(7):1493-7
   PubMed Web of Science ®Google Scholar
• Theoleyre S, Wittrant Y, Tat SK, The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 2004;15(6):457-75
   PubMed Web of Science ®Google Scholar
• Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2008;29(2):155-92
   PubMed Web of Science ®Google Scholar
• Zhao H, Kitaura H, Sands MS, Critical role of beta3 integrin in experimental postmenopausal osteoporosis. J Bone Miner Res 2005;20(12):2116-23
   PubMed Web of Science ®Google Scholar
• Zuo C, Huang Y, Bajis R, Osteoblastogenesis regulation signals in bone remodeling. Osteoporos Int 2012;23(6):1653-63
   PubMed Web of Science ®Google Scholar
• Yadav VK, Ryu JH, Suda N, Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 2008;135(5):825-37
   PubMed Web of Science ®Google Scholar
• Oury F, Yadav VK, Wang Y, CREB mediates brain serotonin regulation of bone mass through its expression in ventromedial hypothalamic neurons. Genes Dev 2010;24(20):2330-42
   PubMed Web of Science ®Google Scholar
• van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 2006;79(3):129-37
   PubMed Web of Science ®Google Scholar
• Donovan MA, Dempster D, Zhou H, Low bone formation in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab 2005;90(6):3331-6
   PubMed Web of Science ®Google Scholar
• Marie PJ, Kassem M. Osteoblasts in osteoporosis: past, emerging, and future anabolic targets. Eur J Endocrinol 2011;165(1):1-10
   PubMed Web of Science ®Google Scholar
• Bonewald LF. Chapter 4. Osteocytes. American Society for Bone and Mineral Research; Washington, DC: 2008. p. 22-7
   Google Scholar
• Amgen, inc. Prolia(R) Prescribing Information. Available from: http://pi.amgen.com/united_states/xgeva/xgeva_pi.pdf [Accessed August 2012]
   Google Scholar
• Amgen, inc. Xgeva(R) Prescribing Information. Available from: http://pi.amgen.com/united_states/xgeva/xgeva_pi.pdf [Accessed August 2012]
   Google Scholar
• Bekker PJ, Holloway DL, Rasmussen AS, A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004;19(7):1059-66
   PubMed Web of Science ®Google Scholar
• McClung MR, Lewiecki EM, Cohen SB, Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354(8):821-31
   PubMed Web of Science ®Google Scholar
• Lewiecki EM, Miller PD, McClung MR, Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low bone mineral density. J Bone Miner Res 2007;22:1832-41
   PubMed Web of Science ®Google Scholar
• Miller PD, Bolognese MA, Lewiecki EM, Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008;43(2):222-9
   PubMed Web of Science ®Google Scholar
• Miller PD, Wagman RB, Peacock M, Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab 2011;96(2):394-402
   PubMed Web of Science ®Google Scholar
• McClung MR, Lewiecki EM, Geller ML, Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int 2012; [Epub ahead of print]
   Web of Science ®Google Scholar
• Papapoulos S, Chapurlat R, Libanati C, Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 2012;27(3):694-701
   PubMed Web of Science ®Google Scholar
• Brown JP, Bone HG, Chapurlat R, Six years of denosumab treatment in postmenopausal women with osteoporosis: results from the the first three years of the FREEDOM extension. Arthritis Rheum 2011;63(12):4044-5
   Web of Science ®Google Scholar
• Bone HG, Bolognese MA, Yuen CK, Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008;93(6):2149-57
   PubMed Web of Science ®Google Scholar
• Brown JP, Prince RL, Deal C, Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009;24(1):153-61
   PubMed Web of Science ®Google Scholar
• Kendler DL, Roux C, Benhamou CL, Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010;25(1):72-81
   PubMed Web of Science ®Google Scholar
• Orwoll E, Teglbjaerg CS, Langdahl BL, A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 2012;97(9):3161-9
   PubMed Web of Science ®Google Scholar
• Leder B, Uihlein A, Neer R, The effects of combined denosumab and teriparatide administration on bone mineral density in postmenopausal women: the DATA (Denosumab And Teriparatide Administration) study. J Bone Miner Res 2012;27(Suppl 1):S31
   Google Scholar
• Black DM, Greenspan SL, Ensrud KE, The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349(13):1207-15
   PubMed Web of Science ®Google Scholar
• Miller P, Bolognese M, Lewiecki EM, Effect of denosumab on bone mineral density and bone turnover markers: 48-month results. J Bone Miner Res 2007;22(Suppl 1):S58
   Google Scholar
• Amgen Inc. Prolia® (denosumab) injection important safety information. Available from: http://pi.amgen.com/united_states/prolia/prolia_isi.pdf [Accessed August 2012]
   Google Scholar
• Brown J, Wagman R, Dempster D, Effects of 5 years of denosumab on bone histology and histomorphometry: the FREEDOM study extension. J Bone Miner Res 2012;27(Suppl 1):S44-5
   Google Scholar
• Holz JB. Safety, pharmacokinetics and efficacy of anti-RANKL Nanobody(R) ALX-0141 in healthy postmenopausal women. Available from: http://www.ablynx.com/wp-content/uploads/2011/05/2011-05-27-ALX-0141-EULAR_final.pdf [Accessed August 2012]
   Google Scholar
• Hsu YH, Chen WY, Chan CH, Anti-IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss. J Exp Med 2011;208(9):1849-61
   PubMed Web of Science ®Google Scholar
• Veverka V, Henry AJ, Slocombe PM, Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. J Biol Chem 2009;284(16):10890-900
   PubMed Web of Science ®Google Scholar
• Li X, Ominsky MS, Warmington KS, Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009;24(4):578-88
   PubMed Web of Science ®Google Scholar
• Ominsky MS, Vlasseros F, Jolette J, Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 2010;25(5):948-59
   PubMed Web of Science ®Google Scholar
• Agholme F, Li X, Isaksson H, Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res 2010;25(11):2412-18
   PubMed Web of Science ®Google Scholar
• Li C, Li X, Xiang J, Systemic treatment with a sclerostin monoclonal antibody enhances fracture healing in the rat femoral closed fracture model. J Bone Miner Res 2009;24(Suppl 1):S352-S353. Available from: http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx? Aid=86bc90c6-c865-462c-8174-e3c1b1029b63
   Google Scholar
• Ominsky M, Samadfan R, Jolette J, Sclerostin monoclonal antibody stimulates bone formation and improves the strength and density of the fracture callus and lumbar spine in a primate fibular osteotomy model. J Bone Miner Res 2009;24(Suppl 1):S89-S90. Available from: http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid¼169908cb-ad5c-4ef9-a499-be570135fa1d
   Google Scholar
• Padhi D, Jang G, Stouch B, Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011;26(1):19-26
   PubMed Web of Science ®Google Scholar
• McClung MR, Grauer A, Boonen S, Inhibition of sclerostin with AMG 785 in postmenopausal women with low bone mineral density: phase 2 trial results. J Bone Miner Res 2012;27(Suppl 1):S8
   Google Scholar
• McColm J, Womack T, Hu L, Blosozumab, a humanized monoclonal antibody against sclerostin, demonstrated anabolic effects on bone in postmenopausal women. J Bone Miner Res 2012;27(Suppl 1):S9
   Google Scholar
• Idolazzi L, Mahamid H, Povino MR, Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab. J Bone Miner Res 2012;27(Suppl 1):S329
   Google Scholar
• Ke HZ, Richards WG, Li X, Ominsky MS. Sclerostin and dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 2012;33(5):747-83
   PubMed Web of Science ®Google Scholar
• Glantschnig H, Scott K, Hampton R, A rate-limiting role for DKK1 in bone formation and the remediation of bone loss in mouse and primate models of postmenopausal osteoporosis by an experimental therapeutic antibody. J Pharmacol Exp Ther 2011;338(2):568-78
   PubMed Web of Science ®Google Scholar
• Tian E, Zhan F, Walker R, The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349(26):2483-94
   PubMed Web of Science ®Google Scholar
• Fulciniti M, Tassone P, Hideshima T, Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009;114(2):371-9
   PubMed Web of Science ®Google Scholar
• Goldhahn J, Feron JM, Kanis J, Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper. Calcif Tissue Int 2012;90(5):343-53
   PubMed Web of Science ®Google Scholar
• Gerstenfeld LC, Sacks DJ, Pelis M, Comparison of Effects of the Bisphosphonate Alendronate Versus the RANKL Inhibitor Denosumab on Murine Fracture Healing. J Bone Miner Res 2009;24(2):196-208
   PubMed Web of Science ®Google Scholar
• Adami S, Libanati C, Adachi J, Denosumab administration is not associated with fracture healing complications in postmenopausal women with osteoporosis: results from the3 FREEDOM trial. J Bone Miner Res 2012;25(Suppl 1):S478
   Google Scholar
• Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256(5517):495-7
   PubMed Web of Science ®Google Scholar
• Buss NA, Henderson SJ, McFarlane M, Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol 2012;12(5):615-22
   PubMed Web of Science ®Google Scholar
• Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984;81(21):6851-5
   PubMed Web of Science ®Google Scholar
• Baker MP, Reynolds HM, Lumicisi B, Bryson CJ. Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self Nonself 2010;1(4):314-22
   PubMedGoogle Scholar
• Deng R, Jin F, Prabhu S, Iyer S. Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development? Expert Opin Drug Metab Toxicol 2012;8(2):141-60
   PubMed Web of Science ®Google Scholar
• Lewiecki EM. New targets for intervention in the treatment of postmenopausal osteoporosis. Nat Rev Rheumatol 2011;7(11):631-8
   PubMed Web of Science ®Google Scholar
• Josse RJ. The role of RANK/RANKL/OPG pathway in bone loss: new insights. Available from: http://www.healthplexus.net/files/content/2009/CGS/Josse.pdf#view=fitV&pagemode=thumbs [Accessed September 2012]
   Google Scholar
• Mason JJ, Williams BO. SOST and DKK: antagonists of LRP family signaling as targets for treating bone disease. J Osteoporos 2010;2010:1-9
   Google Scholar